Treatment of Classical Hodgkin Lymphoma in Children and Adolescents (Age 18 or Younger) with Relapsed or Refractory Disease

This protocol covers subsequent therapy for children and adolescents aged 18 years or younger with classical Hodgkin lymphoma where the disease has relapsed after prior treatment or has been refractory — meaning it did not respond to initial treatment.

Clinical scenario: A patient aged 18 years or younger with classical Hodgkin lymphoma whose disease has either come back after treatment (relapsed) or failed to respond to the initial therapeutic course (refractory). This specific age group requires a tailored approach to subsequent therapy distinct from adult protocols.

Subsequent Therapy — Partial Overview

Structured options exist spanning both combination chemotherapy regimens and immunotherapy-based agents. The protocol defines the specific regimens considered in this setting and the clinical context for each.

Full regimen list, selection criteria, and decision points are available in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

Treatments for Children and Adolescents with Relapsed or Refractory Classical Hodgkin Lymphoma.
Treatment options for children and adolescents whose disease has relapsed (come back after treatment) or is refractory (did not respond to initial treatment).
Subsequent Therapy Options (in alphabetical order): Bortezomib, ifosfamide, vinorelbine, EPIC (etoposide, prednisolone, ifosfamide, cisplatin), GDP (gemcitabine, dexamethasone, cisplatin), ICE (ifosfamide, carboplatin, etoposide), Nivolumab, Pembrolizumab.

View source ↗